Seeking Alpha: Shedding A Little Light On Under-Followed DUSA Pharmaceuticals

There are certain dusty corners of biopharma where most investors just don't look all that often, and eye care and skin care are high on the list. While the addressable markets are well short of what investors expect from areas like oncology or autoimmune disease, the relative lack of competition can make these profitable niches. As under-followed ISTA Pharmaceuticals (ISTA) recently rode a limited roster of products to a worthwhile takeout price, investors may want to consider DUSA Pharmaceuticals (DUSA) for similar potential.

Read more here:
Shedding A Little Light On Under-Followed DUSA Pahrmaceuticals